Cryofocus Medtech (Shanghai) Co., Ltd. has officially released its Articles of Association, detailing core company provisions, share capital structures, and governance protocols. According to the document, the company registered in Shanghai on July 19, 2021, and holds 239,110,000 shares following an overseas issuance. Each share carries a par value of RMB1.

The Articles describe the company’s focus on research, production, and sales related to minimally invasive cryoablation technology. It stipulates a nine-member Board, including four independent directors, each serving a three-year term. The document outlines procedures for general meetings, the scope of the Board’s authority, and agendas that require shareholder approval.

Key provisions address share transfers, dividend distributions, and financial reporting practices in accordance with relevant laws and regulations. Details on capital reduction, share buyback protocols, and liquidation procedures are also included. Additionally, the Articles establish the roles of the general manager and company secretary, emphasizing oversight and disclosure requirements. The entire Articles of Association will govern future operations and ensure compliance with applicable regulations.